A digital approach to characterizing multiple sclerosis symptoms: the example of the MSCopilot® medical device

MSCopilot® digital biomarkers can classify patients according to their disability levels in multiple sclerosis.

The MSCopilot® medical device, whose clinical validity has been established, was presented in September 2025 at the ECTRIMS Congress in Barcelona, Spain. It allows patients with multiple sclerosis to assess their symptoms remotely.

With its digital biomarkers covering motor skills, cognition, dexterity, and vision, it promises to become a key tool for monitoring the progression of the disease.